Pfizer Inc.
SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS
Last updated:
Abstract:
The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.
Status:
Application
Type:
Utility
Filling date:
20 Feb 2020
Issue date:
14 Jan 2021